



RECEIVED 5 MAY 1999 PCTAGB 99 / 01308
The Patent Office WIPO PCT 21 APRIL 1999
09/674559

GB99/1308

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office INVESTOR IN PEOPLE
Concept House
Cardiff Road
Newport
South Wales
NP9 1RH

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed *Andrew Garside*

Dated 30 MAR 1999



- 2 MAY 1998 -

H

THE PATENT OFFICE

05MAY98 E357541-4 D02934
P01/7700 25.00 - 9809351.1**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

02 MAY 1998

Cardiff Road
Newport
Gwent NP9 1RH1. Your reference
PHM 98-0282. Patent application number
(The Patent Office will fill in this part)**9809351.1**3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

ZENECA Limited
15 Stanhope Gate
LONDON W1Y 6LN, Great Britain
Patents ADP number (*if you know it*)
6254007002

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

HETEROCYCLIC DERIVATIVES

5. Name of your agent (*if you have one*)
DENERLEY, Paul Millington

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)
Intellectual Property Department
ZENECA Pharmaceuticals
Mereside, Alderley Park
Macclesfield, Cheshire, SK10 4TG, Great Britain
Patents ADP number (*if you know it*) 1030618002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number
(*if you know it*)Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 25 *ff*

Claim(s)

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination
(*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Lynda May Slack

Date 1 May 1998

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs Lynda Slack
01625 516173

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

HETEROCYCLIC DERIVATIVES

The invention relates to heterocyclic derivatives, or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful 5 in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

The antithrombotic and anticoagulant effect produced by the compounds of the 10 invention is believed to be attributable to their strong inhibitory effect against the activated coagulation protease known as Factor Xa. Factor Xa is one of a cascade of proteases involved in the complex process of blood coagulation. The protease known as thrombin is the final protease in the cascade and Factor Xa is the preceding protease which cleaves prothrombin to generate thrombin.

15 Certain compounds are known to possess Factor Xa inhibitory properties and the field has been reviewed by R.B. Wallis, Current Opinion in Therapeutic Patents, 1993, 1173-1179. Thus it is known that two proteins, one known as antistatin and the other known as tick anticoagulant protein (TAP), are specific Factor Xa inhibitors which possess antithrombotic properties in various animal models of thrombotic disease.

20 It is also known that certain non-peptidic compounds possess Factor Xa inhibitory properties. Of the low molecular weight inhibitors mentioned in the review by R.B. Wallis, all possessed a strongly basic group such as an amidinophenyl or amidinonaphthyl group.


We have now found that certain heterocyclic derivatives possess Factor Xa inhibitory activity. Many of the compounds of the present invention also possess the advantage of being 25 selective Factor Xa inhibitors, that is the enzyme Factor Xa is inhibited strongly at concentrations of test compound which do not inhibit or which inhibit to a lesser extent the enzyme thrombin which is also a member of the blood coagulation enzymatic cascade.

The compounds of the present invention possess activity in the treatment or prevention of a variety of medical disorders where anticoagulant therapy is indicated, for 30 example in the treatment or prevention of thrombotic conditions such as coronary artery and cerebro-vascular disease. Further examples of such medical disorders include various cardiovascular and cerebrovascular conditions such as myocardial infarction, the formation of

atherosclerotic plaques, venous or arterial thrombosis, coagulation syndromes, vascular injury including reocclusion and restenosis following angioplasty and coronary artery bypass surgery, thrombus formation after the application of blood vessel operative techniques or after general surgery such as hip replacement surgery, the introduction of artificial heart valves or on the recirculation of blood, cerebral infarction, cerebral thrombosis, stroke, cerebral embolism, pulmonary embolism, ischaemia and angina (including unstable angina).

The compounds of the invention are also useful as inhibitors of blood coagulation in an ex-vivo situation such as, for example, the storage of whole blood or other biological samples suspected to contain Factor Xa and in which coagulation is detrimental.


10 Accordingly in one aspect the present invention provides compounds of formula (I)




wherein:

15 A is an optionally substituted 5- or 6-membered monocyclic aromatic ring containing 1, 2 or 3 ring heteroatoms selected from nitrogen, oxygen and sulphur atoms;
 B is CH or N (preferably B is N);
 C is optionally substituted 2-indolyl, 2-benzimidazolyl, 2-benzo[b]furanyl, 2-pyrrolo[2,3-b]pyridyl, 2-furo[2,3-b]pyridyl or 6,7H-cyclopenta[b]pyridyl; and pharmaceutically acceptable
 20 salts thereof.


For the avoidance of doubt substituents C are drawn below:




2-indolyl




2-benzimidazolyl




2-benzo[b]furanyl



2-pyrrolo[2,3-b]pyridyl



2-furo[2,3-b]pyridyl



6,7H-cyclopenta[b]pyridyl

5

In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. An analogous convention applies to other generic terms.

It is to be understood that certain heterocyclic derivatives of the present invention
10 can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess Factor Xa inhibitory activity.

It is further to be understood that, insofar as certain of the compounds of the formula defined above may exist in optically active or racemic forms by virtue of one or more
15 asymmetric carbon atoms, the invention encompasses any such optically active or racemic form which possesses Factor Xa inhibitory activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form.

Preferably A is an optionally substituted 5- or 6-membered monocyclic aromatic ring
20 containing 1, 2 or 3 ring nitrogen atoms. Preferably A is a pyridyl, pyrimidinyl, imidazolyl or pyridazinyl ring for example 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 4-pyrimidinyl, 5-pyrimidinyl, 1-imidazolyl, 2-imidazolyl or 4-imidazolyl. Of these 4-pyrimidinyl, 4-pyridazinyl, 1-imidazolyl, 4-imidazolyl, 4-pyridyl are preferred.

In one aspect A is unsubstituted. In another aspect A is substituted by one, two or three atoms or groups selected from halo (for example fluoro, chloro or bromo), oxo, carboxy, trifluoromethyl, cyano, amino, hydroxy, nitro, C₁₋₄alkyl (for example methyl or ethyl), C₁₋₄alkoxy (for example methoxy or ethoxy), C₁₋₄alkoxycarbonyl, C₁₋₄alkylamino (for example 5 methylamino or ethylamino), di-C₁₋₄alkylamino (for example dimethylamino or diethylamino) or amino C₁₋₄alkyl (for example aminomethyl or aminoethyl). For the avoidance of doubt substituents on A may also be present, where possible, on the heteroatom of the ring, such as, for example, N-oxides. Preferred substituents are C₁₋₄alkyl, amino and halo. Preferably A is unsubstituted

10 In one aspect the 1,4-phenylene ring of a compound of formula I is unsubstituted. In another aspect the 1,4-phenylene ring of a compound of formula I is substituted by one or two substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, C₁₋₄alkyl, C₂₋₄alkenyl and C₂₋₄alkynyl, from the substituent -(CH₂)_nY¹ wherein n is 0-4 and Y¹ is selected from hydroxy, amino, carboxy, C₁₋₄alkoxy, C₂₋₄alkenyloxy, C₂₋₄alkynyoxy, C₁₋₄alkylamino, di-C₁₋₄alkylamino, pyrrolidin-1-yl, piperidino, morpholino, thiomorpholino, 1-oxothiomorpholino, 1,1-dioxothiomorpholino, piperazin-1-yl, 4-C₁₋₄alkylpiperazin-1-yl, C₁₋₄alkylthio, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphonyl, C₂₋₄alkanoylamino, benzamido, C₁₋₄alkylsulphonamido and phenylsulphonamido, from the substituent -(CH₂)_nY² wherein n is 0-4 and Y² is selected from carboxy, carbamoyl, C₁₋₄alkoxycarbonyl, N-C₁₋₄alkylcarbamoyl, N,N-di-C₁₋₄alkylcarbamoyl, pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, 1-oxothiomorpholinocarbonyl, 1,1-dioxothiomorpholinocarbonyl, piperazin-1-ylcarbonyl, 4-C₁₋₄alkylpiperazin-1-ylcarbonyl, C₁₋₄alkylsulphonamidocarbonyl, phenylsulphonamidocarbonyl and benzylsulphonamidocarbonyl, from a substituent of the formula -X³-L²-Y² wherein X³ is a group of the formula CON(R⁵), CON(L²-Y²), C(R⁵)₂O, O, 20 N(R⁵) or N(L²-Y²), L² is C₁₋₄alkylene, Y² has any of the meanings defined immediately hereinbefore and each R⁵ is independently hydrogen or C₁₋₄alkyl, and from a substituent of the formula -X³-L³-Y¹ wherein X³ is a group of the formula CON(R⁵), CON(L³-Y¹), C(R⁵)₂O, O, N(R⁵) or N(L³-Y¹), L³ is C₂₋₄alkylene, Y¹ has any of the meanings defined immediately 25 hereinbefore and each R⁵ is independently hydrogen or C₁₋₄alkyl, and wherein any heterocyclic group in a substituent of the 1,4-phenylene ring of compounds of formula I optionally bears 1 or 2 substituents selected from carboxy, carbamoyl, C₁₋₄alkyl, C₁₋₄alkoxycarbonyl, N-C₁₋₄alkylcarbamoyl and N,N-di-C₁₋₄alkylcarbamoyl, and wherein any phenyl group in a substituent

of the 1,4-phenylene ring of compounds of formula I optionally bears 1 or 2 substituents selected from halo, trifluoromethyl, cyano, C₁-alkyl, C₂-alkenyl, C₂-alkynyl, C₁-alkoxy, C₂-alkenyloxy and C₂-alkynyloxy. Preferably the 1,4-phenylene ring of a compound of formula I is substituted by carboxy, C₁-alkoxy or C₁-alkoxycarbonyl. Preferably the 1,4-phenylene ring 5 of a compound of formula I is unsubstituted.

In one aspect the heterocyclic ring containing B is unsubstituted. In another aspect this ring is substituted by one or two substituents selected from hydroxy, oxo, carboxy and C₁-alkoxycarbonyl; or one of the following:

-(CH₂)_n-R, -(CH₂)_n-NRR¹, -CO-R, -CO-NRR¹, -(CH₂)_n-CO-R and -(CH₂)_n-CO-NRR¹;

10 wherein n is 0, 1 or 2, preferably n is 1 or 2;

R and R¹ are independently selected from hydrogen, C₁-alkyl, C₂-alkenyl, C₂-alkynyl, hydroxyC₁-alkyl, carboxyC₁-alkyl and C₁-alkoxycarbonylC₁-alkyl or where possible R and R¹ may together form a 5- or 6-membered optionally substituted saturated or partially unsaturated (preferably saturated) heterocyclic ring which may include in addition to the nitrogen to which 15 R and R¹ are attached 1 or 2 additional heteroatoms selected from nitrogen, oxygen and sulphur.

In a particular aspect the heterocyclic ring formed by R and R¹ is preferably selected from 1-pyrrolidinyl, 1-imidazolinyl, 1-piperidino, 1-piperazinyl, 4-morpholino and 4-thiomorpholino. In a particular aspect the heterocyclic ring formed by R and R¹ may be 20 unsubstituted. In an alternative aspect the ring formed by R and R¹ is substituted by 1 or 2 substituents selected from oxo, hydroxy and carboxy. Preferably the heterocyclic ring containing B is substituted by oxo, carboxy, C₁-alkoxy or C₁-alkoxycarbonyl. Preferably the heterocyclic ring containing B is unsubstituted.

In one aspect C is unsubstituted. In another aspect C is substituted by one, two or 25 three substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, oxo, amino, nitro, trifluoromethylsulphonyl, carboxy, carbamoyl, C₁-alkyl, C₂-alkenyl, C₂-alkynyl, C₁-alkoxy, C₂-alkenyloxy, C₂-alkynyloxy, C₁-alkylthio, C₁-alkylsulphanyl, C₁-alkylsulphonyl, C₁-alkylamino, di-C₁-alkylamino, C₁-alkoxycarbonyl, N-C₁-alkylcarbamoyl, N,N-di-C₁-alkylcarbamoyl, C₂-alkanoyl, C₂-alkanoylamino, hydroxyC₁-alkyl, C₁-alkoxyC₁-alkyl, 30 carboxyC₁-alkyl, C₁-alkoxycarbonylC₁-alkyl, carbamoylC₁-alkyl, N-C₁-alkylcarbamoylC₁-alkyl, N,N-di-C₁-alkylcarbamoylC₁-alkyl, phenyl, heteroaryl, phenoxy, phenylthio, phenylsulphanyl, phenylsulphonyl, benzyl, benzoyl, heteroaryloxy, heteroarylthio, heteroarylsulphanyl and

heteroarylsulphonyl, and wherein said heteroaryl substituent or the heteroaryl group in a heteroaryl-containing substituent is a 5- or 6-membered monocyclic heteroaryl ring containing up to 3 heteroatoms selected from nitrogen, oxygen and sulphur, and wherein said phenyl, heteroaryl, phenoxy, phenylthio, phenylsulphiny, phenylsulphonyl, heteroaryloxy, 5 heteroarylothio, heteroarylsulphiny, heteroarylsulphonyl, benzyl or benzoyl substituent optionally bears 1, 2 or 3 substituents selected from halo, trifluoromethyl, cyano, hydroxy, amino, nitro, carboxy, carbamoyl, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkylamino, di-C₁₋₄alkylamino, C₁₋₄alkoxycarbonyl, N-C₁₋₄alkylcarbamoyl, N,N-di-C₁₋₄alkylcarbamoyl and C₂₋₄ alkanoylamino. Preferably C is substituted by halo.

10 Suitable values for optional substituents for the 1,4-phenylene ring and C of compounds of formula I are:

for C ₁₋₄ alkyl:	methyl, ethyl and propyl;
for C ₁₋₄ alkoxycarbonyl:	methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and <u>tert</u> -butoxycarbonyl;
15 for <u>N</u> -C ₁₋₄ alkylcarbamoyl:	<u>N</u> -methylcarbamoyl, <u>N</u> -ethylcarbamoyl and <u>N</u> -propylcarbamoyl;
for <u>N,N</u> -di-C ₁₋₄ alkylcarbamoyl:	<u>N,N</u> -dimethylcarbamoyl, <u>N</u> -ethyl- <u>N</u> -methylcarbamoyl and <u>N,N</u> -diethylcarbamoyl;
20 for hydroxyC ₁₋₄ alkyl:	hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 3-hydroxypropyl;
for C ₁₋₄ alkoxyC ₁₋₄ alkyl:	methoxymethyl, ethoxymethyl, 1-methoxymethyl, 2-methoxyethyl, 2-ethoxyethyl and 3-methoxypropyl;
25 for carboxyC ₁₋₄ alkyl:	carboxymethyl, 1-carboxyethyl, 2-carboxyethyl and 3-carboxypropyl;
for C ₁₋₄ alkoxycarbonylC ₁₋₄ alkyl:	methoxycarbonylmethyl, ethoxycarbonylmethyl, <u>tert</u> -butoxy carbonylmethyl, 1-methoxycarbonylethyl, 1-ethoxycarbonylethyl, 2-methoxycarbonylethyl,
30	

for carbamoylC₁-alkyl:

2-ethoxycarbonylethyl,
3-methoxycarbonylpropyl and
3-ethoxycarbonylpropyl;
carbamoylmethyl, 1-carbamoylethyl,
2-carbamoylethyl and
3-carbamoylpropyl;

for N-C₁-alkylcarbamoylC₁-alkyl:

N-methylcarbamoylmethyl,
N-ethylcarbamoylmethyl,
N-propylcarbamoylmethyl,
1-(N-methylcarbamoyl)ethyl,
1-(N-ethylcarbamoyl)ethyl,
2-(N-methylcarbamoyl)ethyl,
2-(N-ethylcarbamoyl)ethyl and
3-(N-methylcarbamoyl)propyl;

10 for N,N-di-C₁-alkylcarbamoyl-C₁-alkyl:

N,N-dimethylcarbamoylmethyl,
N-ethyl-N-methylcarbamoylmethyl,
N,N-diethylcarbamoylmethyl,
1-(N,N-dimethylcarbamoyl)ethyl,
1-(N,N-diethylcarbamoyl)ethyl,
2-(N,N-dimethylcarbamoyl)ethyl,
2-(N,N-diethylcarbamoyl)ethyl and
3-(N,N-dimethylcarbamoyl)propyl;

15 for halo:

fluoro, chloro, bromo;

for C₁-alkoxy:

methoxy, ethoxy;

20 for C₁-alkylamino:

methylamino, ethylamino;

for di-C₁-alkylamino:

dimethylamino, diethylamino;

for C₁-alkenyl:

vinyl and allyl;

for C₂-alkynyl:

ethynyl and prop-2-yynyl;

for C₂-alkenyloxy:

vinyloxy and allyloxy;

25 for C₂-alkynyloxy:

ethynyoxy and prop-2-ynyloxy;

for C₁-alkylthio:

methylthio, ethylthio and propylthio;

for C₁-alkylsulphanyl:

methylsulphanyl, ethylsulphanyl and propylsulphanyl;

for C₁-alkylsulphonyl:

methylsulphonyl, ethylsulphonyl and propylsulphonyl;

5 for C₂-alkanoylamino:

acetamido, propionamido and butyramido;

A preferred class of compounds of the present invention is that wherein:

A is pyridyl, pyrimidinyl, imidazolyl or pyridazinyl;

B is N;

C is 2-indolyl, or 2-benzo[b]furanyl optionally substituted by fluoro, chloro or bromo;

10 and pharmaceutically-acceptable salts thereof.

Particular compounds of the invention include:

1-(5-chlorobenzo[b]furan-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl]piperazine;

1-(5-chlorobenzo[b]furan-2-ylsulphonyl)-4-[4-(1-imidazolyl)benzoyl]piperazine;

1-(5-chloroindol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine;

15 1-(5-chloroindol-2-ylsulphonyl)-4-[4-(4-pyrimidyl)benzoyl] piperazine;

1-(5-chloroindol-2-ylsulphonyl)-4-[4-(4-pyridazinyl)benzoyl] piperazine;

1-(5-chloroindol-2-ylsulphonyl)-4-[4-(1-imidazolyl)benzoyl] piperazine;

1-(5-chloroindol-2-ylsulphonyl)-4-[4-(4-imidazolyl)benzoyl] piperazine;

1-(5-chlorobenzo[b]furan-2-ylsulphonyl)-4-[4-(2-methylimidazol-4-yl)benzoyl]piperazine;

20 1-(5-fluroindol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine;

1-(5-chloroindol-2-ylsulphonyl)-4-[4-(2-methylimidazol-4-yl)benzoyl] piperazine;

1-(5-chlorobenzo[b]furan-2-ylsulphonyl)-4-[4-(4-imidazolyl)benzoyl]piperazine;

1-(6-chloroindol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine; and

1-(5-chlorobenzimidazol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine.

25 Particularly preferred compounds of the invention are;

1-(5-chlorobenzo[b]furan-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl]piperazine;

1-(5-chloroindol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine;

1-(5-chloroindol-2-ylsulphonyl)-4-[4-(4-pyrimidyl)benzoyl] piperazine; and

1-(5-chloroindol-2-ylsulphonyl)-4-[4-(4-pyridazinyl)benzoyl] piperazine.

30 A heterocyclic derivative of formula I, or pharmaceutically-acceptable salt thereof,

may be prepared by any process known to be applicable to the preparation of related


compounds. Such procedures are provided as a further feature of the invention and are

illustrated by the following representative processes in which, unless otherwise stated A, B, and C have any of the meanings defined hereinbefore wherein any functional group, for example amino, alkylamino, carboxy or hydroxy, is optionally protected by a protecting group which may be removed when necessary.


5 Necessary starting materials may be obtained by standard procedures of organic chemistry and by reference to the processes used in the Examples.

According to another aspect, the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, which comprises:

(a) For the production of those compounds of the formula (I) wherein B is N, the
10 reaction, conveniently in the presence of a suitable base, of an amine of formula (II)



with an acid of the formula (III)



or a reactive derivative thereof.

15 A suitable reactive derivative of an acid of the formula (III) is, for example, an acyl halide, for example an acyl chloride formed by the reaction of the acid and an inorganic acid chloride, for example thionyl chloride; a mixed anhydride, for example an anhydride formed by the reaction of the acid with a chloroformate such as isobutyl chloroformate or with an activated amide such as 1,1'-carbonyldiimidazole; an active ester, for example an ester
20 formed by the reaction of the acid and a phenol such as pentafluorophenol, an ester such as pentafluorophenyl trifluoroacetate or an alcohol such as N-hydroxybenzotriazole or N-hydroxysuccinimide; an acyl azide, for example an azide formed by the reaction of the acid and an azide such as diphenylphosphoryl azide; an acyl cyanide, for example a cyanide formed by the reaction of an acid and a cyanide such as diethylphosphoryl cyanide; or the product of
25 the reaction of the acid and a carbodiimide such as N,N'-dicyclohexylcarbodiimide or N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide.

The reaction is conveniently carried out in the presence of a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide, hydroxide or hydride, for

example sodium carbonate, potassium carbonate, sodium ethoxide, potassium butoxide, sodium hydroxide, potassium hydroxide, sodium hydride or potassium hydride, or an organometallic base such as an alkyl-lithium, for example n-butyl-lithium, or a dialkylamino-lithium, for example lithium di-isopropylamide, or, for example, an organic 5 amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine or diazabicyclo[5.4.0]undec-7-ene. The reaction is also preferably carried out in a suitable inert solvent or diluent, for example methylene chloride, chloroform, carbon tetrachloride, tetrahydrofuran, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one, dimethylsulphoxide or acetone, and at a 10 temperature in the range, for example, -78° to 150°C, conveniently at or near ambient temperature.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxy carbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or tert-butoxycarbonyl group, an 15 arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxy carbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. 20 Alternatively an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric, phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable 25 alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.


A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an 30 arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with

a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.

An arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *tert*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

10 (b) The reaction of a compound of the formula (IV):




wherein Z is a displaceable group such as halo, with an activated derivative of ring A. Suitable activated derivatives include metalised derivatives, such as with zinc or tin, and borane derivatives. The activated derivative of ring A is reacted with a compound of the formula (IV) to effect cross coupling where Z is triflate or a halo group, such as iodo, bromo or chloro. Suitably the reaction is catalysed by use of a transition state metal catalyst, such as palladium, for example tetrakis (triphenylphosphine) palladium (0).

20 Alternatively it is possible that ring A contains the displaceable group Z and the phenyl ring is activated, and the reaction performed as described above.

Compounds of the formula (IV) not suitable for this method are those which contain a halo substituent on any of the rings.

(c) By forming A ring on compounds of formula (IV), wherein Z is a functional group capable of cyclisation. Suitable reagents and conditions are described below in preparing compounds of formula (III) by cyclisation.

(d) The reaction of a compound of the formula (V):



with a compound of the formula (VI):



5 wherein Z is a displaceable group for example chloro, under conditions similar to those of process (a) above.

Compounds of formula (II) wherein B is N may be prepared by the reaction of a compound of the formula (VII)



10 , wherein P is a protecting group, with a compound of formula (VI), as defined above, in an analogous manner as described above in method (d) above, and subsequently removing the protecting group.

Compounds of formula (III) may be prepared by the coupling of a compound of formula (VIII), wherein Z is a displaceable group, preferably halo,



15

with an activated derivative of ring A as described, for example, in method (b) above. Ideally the reaction is catalysed with a palladium catalyst. Suitable reagents and conditions are described in Martin A.R.; Acta.Chem.Scand., 47, 221-230, (1993); Mitchell T.N.; Synthesis, 803, (1992) and Stille, J.K., Angew. Chem. Int. Ed. Engl. 25, 508-524, (1986).

20 Suitable non-catalysed coupling reactions include those described in Shiao, M-J. et. al., Synlett., 655, (1992).


Synthesis of stannane intermediates which may be required for palladium catalysed reactions are described in Hylarides, M.D. et. al., Journal of Organometallic Chemistry, 367, 259-265, (1989).

25 Alternatively compounds of formula (III) may be prepared by forming A rings on compounds of formula (VIII), wherein Z is a functional group capable of cyclisation, by cyclisation reaction. Suitable reagents and conditions are described in Bredereck H.

Chem.Ber.; 96, 1505, (1963); Fuchigami, T., Bull. Chem. Soc. Jpn., 49, p3607, (1976); Huffman, K.R., J. Org. Chem., 28, p1812, (1963); Palusso, G., Gazz. Chim. Ital., 90, p1290, (1960) and Ainsworth C., J.Het.Chem., 3, p470, (1966). Such reactions are particularly suited to the formation of 5-membered A rings. Processes suitable for synthesis of starting materials in such cyclisation reactions are described, for example, in Zhang M.Q. et.al; J.Heterocyclic. Chem.; 28, 673, (1991) and Kosugi, M. et al., Bull. Chem. Soc. Jpn., 60, 767-768 (1987).

Compounds of formula (IV) may be prepared by the reaction of a compound of the formula (IX)

10




with a compound of formula (VI), as defined above, in an analogous manner as described above in method (c).

Compounds of formula (IX), where C is CH, may be prepared by the reaction of a compound of the formula (X)

15



with an activated compound of formula (III')



wherin Z is a leaving group, such as methyl or chloride, and subsequently effecting removal of the protecting group, as described in Journal of Chemistry, 42, 1189, (1977).

20 Preferably the compound of formula (VI) is prepared by conversion from the sodium salt of the sulphonic acid or free acid derivative by reacting with thionyl chloride, in the presence of a catalyst, such as dimethyl formamide, in a suitable solvent, such as dichloromethane.

When a pharmaceutically-acceptable salt of a compound of the formula (I) is required, it may be obtained, for example, by reaction of said compound with a suitable acid or base using a conventional procedure.

When an optically active form of a compound of the formula (I) is required, it may be obtained, for example, by carrying out one of the aforesaid procedures using an optically active starting material or by resolution of a racemic form of said compound using a conventional procedure, for example by the formation of diastereomeric salts, use of chromatographic techniques, conversion using chirally specific enzymatic processes, or by addition of temporary extra chiral groupd to aid seperation.

As stated previously, the compounds of the formula (I) are inhibitors of the enzyme Factor Xa. The effects of this inhibition may be demonstrated using one or more of the standard procedures set out hereinafter:-

10

a) Measurement of Factor Xa Inhibition

An in vitro assay system based on the method of Kettner *et al.*, *J. Biol. Chem.*, 1990, 265, 18289-18297, whereby various concentrations of a test compound are dissolved in a pH7.5 buffer containing 0.5% of a polyethylene glycol (PEG 6000) and incubated at 37°C with 15 human Factor Xa (0.001 Units/ml, 0.3 ml) for 15 minutes. The chromogenic substrate S-2765 (KabiVitrum AB, 20 µM) is added and the mixture is incubated at 37°C for 20 minutes whilst the absorbance at 405 nm is measured. The maximum reaction velocity (V_{max}) is determined and compared with that of a control sample containing no test compound. Inhibitor potency is expressed as an IC₅₀ value.

20 b) Measurement of Thrombin Inhibition

The procedure of method a) is repeated except that human thrombin (0.005 Units/ml) and the chromogenic substrate S-2238 (KabiVitrum AB, 7 µM) are employed.

c) Measurement of Anticoagulant Activity

An in vitro assay whereby human, rat or rabbit venous blood is collected and added directly 25 to a sodium citrate solution (3.2 g/100 ml, 9 parts blood to 1 part citrate solution). Blood plasma is prepared by centrifugation (1000 g, 15 minutes) and stored at 2-4°C. Conventional prothrombin time (PT) tests are carried out in the presence of various concentrations of a test compound and the concentration of test compound required to double the clotting time, hereinafter referred to as CT2, is determined. In the PT test, the test compound and blood 30 plasma are incubated at 37°C for 10 minutes. Tissue thromboplastin with calcium (Sigma

Limited, Poole, England) is added and fibrin formation and the time required for a clot to form are determined.

d) Rat Disseminated Intravascular Coagulation in vivo activity test:

5 Fasted male Alderley Park rats (300-450 g) are pre-dosed by oral gavage (5 mls/kg) with compound or vehicle (5% DMSO/PEG200) at various times before being anaesthetised with Intraval® (120 mg/kg i.p.). The left jugular vein and the right carotid artery are exposed and cannulated. A 1 mL blood sample is taken from the carotid canular into 3.2% trisodium citrate. 0.5 mL of the whole blood is then treated with EDTA and used for platelet count 10 determination whilst the remainder is centrifuged (5 mins, 20000g) and the resultant plasma frozen for subsequent drug level, fibrinogen or thrombin antithrombin (TAT) complex determinations. Recombinant human tissue factor (Dade Innovin Cat.B4212-50), reconstituted to the manufacturers specification, is infused (2 mL/kg/hr) into the venous canular for 60 minutes. Immediately after the infusion is stopped a 2 mL blood sample is taken and platelet 15 count, drug level, plasma fibrinogen concentration and TAT complex are determined as before. Platelet counting is performed using a Coulter T540 blood analyser. Plasma fibrinogen and TAT levels are determined using a clotting assay (Sigma Cat.880-B) and TAT ELISA (Behring) respectively. The plasma concentration of the compound is bioassayed using human Factor Xa and a chromogenic substrate S2765 (Kabi), extrapolated from a standard curve 20 (Fragmin) and expressed in Anti-Factor Xa units. The data is analysed as follows; tissue factor-induced reductions in platelet count are normalised with respect to pre-dose platelet count and drug activity expressed as a percent inhibition of tissue factor-induced thrombocytopenia when compared to vehicle treated animals. Compounds are active if there is statistically significant ($p < 0.05$) inhibition of TF-induced thrombocytopenia.

25 e) An ex vivo Assay of Anticoagulant Activity

The test compound is administered intravenously or orally to a group of Alderley Park Wistar rats. At various times thereafter animals are anaesthetised, blood is collected and PT coagulation assays analogous to those described hereinbefore are conducted.

f) An in vivo Measurement of Antithrombotic Activity

30 Thrombus formation is induced using an analogous method to that described by Vogel et al., Thromb. Research, 1989, 54, 399-410. A group of Alderley Park Wistar rats is anaesthetised and surgery is performed to expose the vena cava. Collateral veins are ligated and two loose sutures are located, 0.7 cm apart, round the inferior vena cava. Test

compound is administered intravenously or orally. At an appropriate time thereafter tissue thromboplastin (30 µl/kg) is administered via the jugular vein and, after 10 seconds, the two sutures are tightened to induce stasis within the ligated portion of vena cava. After 10 minutes the ligated tissue is excised and the thrombus therein is isolated, blotted and weighed.

5 In general compounds of the formula I possess activity at the following concentrations or doses in at least one of the above tests a) to c):-

test a): IC₅₀ (Factor Xa) in the range, for example, 0.001-0.1 µM;

test b): IC₅₀ (thrombin), for example, greater than 40 µM;

test c): CT2 (PT) in the range, for example, 0.1-40 µM.

10 A feature of the invention is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in medical therapy.

According to a further feature of the invention there is provided a pharmaceutical composition which comprises a heterocyclic derivative of formula (I), or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable 15 diluent or carrier.

The composition may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use, for example a cream, ointment, gel or aqueous or oily solution or suspension; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for 20 administration by inhalation, for example as a finely divided powder such as a dry powder, a microcrystalline form or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oily solution or suspension. In general the above compositions may be prepared in a conventional manner using conventional 25 excipients.

The amount of active ingredient (that is a heterocyclic derivative of the formula (I), or a pharmaceutically-acceptable salt thereof) that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral 30 administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary

from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient.

According to a further feature of the invention there is provided a heterocyclic derivative of formula (I), or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of the human or animal body by therapy.

The invention also includes the use of such an active ingredient in the production of a medicament for use in:-

- (i) producing a Factor Xa inhibitory effect;
- (ii) producing an anticoagulant effect;
- 10 (iii) producing an antithrombotic effect;
- (iv) treating a Factor Xa mediated disease or medical condition;
- (v) treating a thrombosis mediated disease or medical condition;
- (vi) treating coagulation disorders; and/or
- (vii) treating thrombosis or embolism involving Factor Xa mediated coagulation.

15 The invention also includes a method of producing an effect as defined hereinbefore or treating a disease or disorder as defined hereinbefore which comprises administering to a warm-blooded animal requiring such treatment an effective amount of an active ingredient as defined hereinbefore.

20 The size of the dose for therapeutic or prophylactic purposes of a compound of the formula (I) will naturally vary according to the nature and severity of the medical condition, the age and sex of the animal or patient being treated and the route of administration, according to well known principles of medicine. As mentioned above, compounds of the formula (I) are useful in the treatment or prevention of a variety of medical disorders where anticoagulant therapy is indicated. In using a compound of the formula (I) for such a 25 purpose, it will generally be administered so that a daily oral dose in the range, for example, 0.5 to 100 mg/kg body weight/day is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed, for example a dose for intravenous administration in the range, for example, 0.01 to 10 mg/kg body weight/day will generally be used. For preferred and especially preferred compounds of the invention, in 30 general, lower doses will be employed, for example a daily dose in the range, for example, 0.1 to 10 mg/kg body weight/day. In general a preferred dose range for either oral or parenteral administration would be 0.01 to 10 mg/kg body weight/day.

Although the compounds of formula (I) are primarily of value as therapeutic or prophylactic agents for use in warm-blooded animals including man, they are also useful whenever it is required to produce an anticoagulant effect, for example during the ex-vivo storage of whole blood or in the development of biological tests for compounds having 5 anticoagulant properties.

The compounds of the invention may be administered as a sole therapy or they may be administered in conjunction with other pharmacologically active agents such as a thrombolytic agent, for example tissue plasminogen activator or derivatives thereof or streptokinase. The compounds of the invention may also be administered with, for example, a 10 known platelet aggregation inhibitor (for example aspirin, a thromboxane antagonist or a thromboxane synthase inhibitor), a known hypolipidaemic agent or a known anti-hypertensive agent.

The invention will now be illustrated in the following Examples in which, unless otherwise stated:-

15 (i) yields are given for illustration only and are not necessarily the maximum attainable;

(ii) the end-products of the formula (I) have satisfactory microanalyses and their structures were confirmed by nuclear magnetic resonance (NMR) and mass spectral techniques; unless otherwise stated, CD_3SOCD_3 solutions of the end-products of the formula 20 I were used for the determination of NMR spectral data, chemical shift values were measured on the delta scale; the following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet;

(iii) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, infra-red (IR) or NMR analysis; and

25 (iv) melting points were determined using a Mettler SP62 automatic melting point apparatus or an oil-bath apparatus; melting points for the end-products of the formula I were generally determined after crystallisation from a conventional organic solvent such as ethanol, methanol, acetone, ether or hexane, alone or in admixture.

30 Example 1 1-(5-Chlorobenzof[b]furan-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl]piperazine

A stirred suspension of 4-(4-pyridyl)benzoic acid (133 mg, 0.67 mmol) in dimethylformamide (5 ml) was treated sequentially with 1-hydroxybenzotriazole hydrate (HOBT, 108 mg, 0.8 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDAC, 153 mg, 0.8 mmol) and 1-(5-chlorobenzo[b]furan-2-ylsulphonyl) piperazine (201 mg, 0.67 mmol). After stirring overnight the solvent was removed *in vacuo* and the residue chromatographed (Merck Art 9385 silica, eluting with dichloromethane containing 2% v/v of methanol) to yield 1-(5-chlorobenzo[b]furan-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine as a colourless solid (40 mg), ^1H NMR (CDCl_3) δ = 3.2-3.4 ppm (broad s, 4H), δ = 3.6-4.0 ppm (broad s, 4H), δ = 7.35 ppm (s, 1H), δ = 7.5 ppm (m, 6H), δ = 7.7 ppm (m, 3H), δ = 8.7 ppm 10 (d, 2H), MS ($\text{M}+\text{H}$) $^+$ 482/484.

The requisite 1-(5-chlorobenzo[b]furan-2-ylsulphonyl) piperazine starting material was prepared as follows:

15

A stirred solution of piperazine (1.15g, 13.4 mmol) and triethylamine (4.7 ml, 46.5 mmol) in dichloromethane (30 ml) was cooled to ~5 °C, and a solution of 5-chlorobenzo[b]furan-2-sulphonyl chloride (1.69g, 7.8 mmol) in dichloromethane (10 ml) was added. Stirring was continued for 15 mins, and the reaction mixture then allowed to warm to ambient temperature 20 over 2 hrs with stirring. Water was added to the reaction mixture, and the organic layer separated; this was washed with water (twice), brine (once), then dried (MgSO_4), filtered and evaporated to give a yellow gum. This was chromatographed (Merck Art 9385 silica, eluting with dichloromethane containing increasing amounts of methanol, up to 10% v/v) to give a yellow solid; trituration with diethyl ether gave 5-chlorobenzo[b]furan-2-ylsulphonyl piperazine 25 as a colourless solid (1.11g) which was used without further purification, ^1H NMR (CDCl_3) δ = 2.8 - 3.0 ppm (t, 4H), δ = 3.2 - 3.4 ppm (t, 4H), δ = 7.3 ppm (s, 1H), δ = 7.45 ppm (dd, 2H), δ = 7.7 ppm (s, 1H); MS ($\text{M}+\text{H}$) $^+$ 301/303.

The requisite 5-chlorobenzo[b]furan-2-sulphonyl chloride starting material was prepared as 30 described in European Patent Application 0 355 827 (Mochida, Hydantoin derivatives).

Example 2 1-(5-Chlorobenzo[b]furan-2-ylsulphonyl)-4-[4-(1-imidazolyl)benzoyl]piperazine

To a suspension of 4-(1-imidazolyl)benzoic acid hydrochloride (225mg, 1 mmol.) in dimethylformamide (6ml) was added 1-(5-chlorobenzo[b]furan-2-ylsulphonyl) piperazine (315mg, 1.05 mmol), 1-hydroxybenzotriazole hydrate (150mg, 1 mmol), triethylamine (0.2 ml, 1.5 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodi-imide hydrochloride (EDAC, 210mg, 1.1 mmol), and the resultant suspension stirred overnight. The reaction mixture was poured into water, and the precipitated solid filtered off and washed with water to give (after drying) 550mg of colourless solid.

10

This was purified by flash chromatography using an ISOLUTE 20g silica column, eluting with dichloromethane containing methanol (2.5%), giving 330mg of essentially pure product. This was crystallised from 2-propanol to give (220 mg, 47% yield) 1-(5-chlorobenzo[b]furan-2-ylsulphonyl)-4-[4-(1-imidazolyl)benzoyl]piperazine as colourless prisms, m.p. 175 - 177 °C,

15 ¹H NMR (⁶DMSO) δ = 3.3 ppm (sharp s, 4H), δ = 3.4 - 3.8 ppm (broad s, 4H), δ = 7.1 ppm (s, 1H), δ = 7.55 ppm (d, 2H), δ = 7.6 ppm (dd, 1H), δ = 7.7 ppm (m, 3H), δ = 7.8 ppm (m, 2H), δ = 7.9 ppm (d, 1H), δ = 8.3 ppm (s, 1H); MS (M+H)⁺ 470/472.

The requisite 4-(1-imidazolyl)benzoic acid starting material may prepared as described in J.

20 Med. Chem. 33 1091 (1990).

Example 3 1-(5-Chloroindol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine

A stirred suspension of 4-(4-pyridyl)benzoic acid (252 mg, 1.27 mmol) in dimethylformamide (10 ml) was treated sequentially with 1-(5-chloroindol-2-ylsulphonyl) piperazine (380mg, 1.27 mmol), 1-hydroxybenzotriazole hydrate (HOBT, 271 mg, 1.77 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodi-imide hydrochloride (EDAC, 291 mg, 1.52 mmol). After stirring overnight the solvent was removed *in vacuo* and the residue taken up in dichloromethane (50ml). This was washed sequentially with water, saturated sodium bicarbonate solution, water and brine. Evaporation of the solvent gave a residue which was chromatographed (MPLC on Merck Art 9385 silica, gradient eluting with dichloromethane

containing 0-3.5% v/v of methanol) to yield, after crystallisation from acetone, 1-(5-chloroindol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine as colourless crystals (244 mg),
 m.p. 185-188 °C, ^1H NMR (d_6DMSO) δ = 3.0-3.2 ppm (broad s, 4H), δ = 3.4-3.8 ppm (broad s, 4H), δ = 7.0 ppm (s, 1H), δ = 7.3 ppm (dd, 1H), δ = 7.5 ppm (m, 3H), δ = 7.7 ppm (m, 2H), δ = 7.8 ppm (m, 3H), δ = 8.6 ppm (m, 2H), δ = 12.4 ppm (broad s, 1H), the spectrum also contained a signal due to acetone, ca 0.5 mol. eq.; Microanalysis, found: C, 59.9; H, 4.4; N, 10.6; S, 6.1 %; $\text{C}_{24}\text{H}_{21}\text{N}_4\text{O}_3\text{ClS}$. 0.5 $\text{C}_3\text{H}_6\text{O}$ requires: C, 60.1; H, 4.7; N, 11.0; S, 6.3 %; MS ($\text{M}+\text{H}$) $^+$ 481/483.

10 The requisite 1-(5-chloroindol-2-ylsulphonyl) piperazine starting material was prepared as follows:

1-(1-benzenesulphonyl-5-chloroindol-2-ylsulphonyl) piperazine (4.15g, 9.44 mmol) was treated with sodium hydroxide solution (32 ml of 2.5M), giving a yellow suspension. This was warmed to 80 °C with vigorous stirring and stirred for 45 mins, giving complete solution. The solution was cooled to ambient temperature and carefully treated with concentrated hydrochloric acid to pH 8; the resultant precipitate was filtered off, washed with water and dried to give 1-(5-chloroindol-2-ylsulphonyl) piperazine as a pale yellow solid, ^1H NMR (d_6DMSO) δ = 2.75 ppm (m, 4H), δ = 2.9 ppm (m, 4H), δ = 7.0 ppm (s, 1H), δ = 7.3 ppm (dd, 1H), δ = 7.5 ppm (d, 1H), δ = 7.8 ppm (d, 1H); MS ($\text{M}+\text{H}$) $^+$ 300/302.

The requisite 1-(1-benzene sulphonyl-5-chloroindol-2-ylsulphonyl) piperazine starting material was prepared as follows:

25 A solution of 1-benzene sulphonyl-5-chloroindol-2-ylsulphonyl chloride (10.0g, 25.6 mmol) in dichloromethane (100ml) was added dropwise to a stirred solution of piperazine (13.23g, 6eq.) in dichloromethane (200ml), and the mixture stirred for a further 2 hrs. The reaction mixture was then washed with water (3x200ml), dried (Phase-Separating paper) and evaporated to give a red oil which was purified by flash chromatography using Merck silica (Art. 9385), eluting
 30 with dichloromethane containing methanol (0-6%), to give 1-(1-benzene sulphonyl-5-chloroindol-2-ylsulphonyl) piperazine as a colourless solid, ^1H NMR (CDCl_3) δ = 2.95 ppm

(m, 4H), δ = 3.4 ppm (m, 4H), δ = 7.4 ppm (m, 4H), δ = 7.55 ppm (m, 2H), δ = 8.0 ppm (d, 2H), δ = 8.0 ppm (d, 1H); MS (M+H)⁺ 440/442.

The requisite 1-benzene sulphonyl-5-chloroindol-2-ylsulphonyl chloride starting material may
5 be prepared by a method analogous to that reported in J. Med. Chem. 33 749 (1990), starting from 5-chloroindole.

Example 4 1-(5-Chloroindol-2-ylsulphonyl)-4-[4-(4-pyrimidyl)benzoyl] piperazine

10 By an exactly analogous method, starting from 4-(4-pyrimidyl)benzoic acid,
was prepared 1-(5-chloroindol-2-ylsulphonyl)-4-[4-(4-pyrimidyl)benzoyl] piperazine as
colourless crystals (230 mg) from acetone, m.p. 229-230 °C, ¹H NMR (d₆DMSO) δ = 3.0-3.2
ppm (broad s, 4H), δ = 3.4-3.8 ppm (broad s, 4H), δ = 7.0 ppm (s, 1H), δ = 7.3 ppm (dd, 1H),
7.5 ppm (m, 3H), δ = 7.8 ppm (s, 1H), δ = 8.1 ppm (d, 1H), δ = 8.2 ppm (d, 2H), δ = 8.9 ppm
15 (d, 1H), δ = 9.3 ppm (s, 1H), δ = 12.4 ppm (broad s, 1H), the spectrum also contained a signal
due to acetone, ca 0.2 mol. eq.; microanalysis, found: C, 56.7; H, 4.2; N, 14.2; S, 6.5 %;
C₂₃H₂₀N₅O₃ClS. 0.2 C₃H₆O requires: C, 57.1; H, 4.2; N, 14.1; S, 6.5 %; MS (M+H)⁺
482/484.

20 **Example 5 1-(5-Chloroindol-2-ylsulphonyl)-4-[4-(4-pyridazinyl)benzoyl] piperazine**

By an exactly analogous method, starting from 4-(4-pyridazinyl)benzoic acid,
was prepared 1-(5-chloroindol-2-ylsulphonyl)-4-[4-(4-pyridazinyl)benzoyl] piperazine as
colourless crystals (370 mg) from acetone, m.p. 170-172 °C, ¹H NMR (d₆DMSO) δ = 3.0-3.2
25 ppm (broad s, 4H), δ = 3.4-3.8 ppm (broad s, 4H), δ = 7.0 ppm (s, 1H), δ = 7.3 ppm (d, 1H),
7.5 ppm (m, 3H), δ = 7.8 ppm (s, 1H), δ = 7.95 ppm (d, 2H), δ = 8.0 ppm (dd, 1H), δ =
9.3 ppm (d, 1H), δ = 9.6 ppm (s, 1H), δ = 12.4 ppm (broad s, 1H), the spectrum also
contained a signal due to acetone, ca 1.0 mol. eq.; MS (M+H)⁺ 482/484.

30 **Example 6 1-(5-Chloroindol-2-ylsulphonyl)-4-[4-(1-imidazolyl)benzoyl] piperazine**

By an analogous method, starting from 4-(1-imidazolyl)benzoic acid hydrochloride and 1-(5-chloroindol-2-ylsulphonyl) piperazine, was prepared 1-(5-chloroindol-2-ylsulphonyl)-4-[4-(1-imidazolyl)benzoyl] piperazine (375 mg, 60% yield) as colourless crystals from acetone; m.p. 155-165 °C, ¹H NMR (d₆DMSO) δ = 3.0 - 3.2 ppm (broad s, 4H), δ = 3.4 - 3.8 ppm (broad s, 4H), δ = 7.0 ppm (s, 1H), δ = 7.1 ppm (s, 1H), δ = 7.3 ppm (dd, 1H), 7.5 ppm (m, 3H), δ = 7.7 ppm (d, 2H), δ = 7.8 ppm (m, 2H), δ = 8.3 ppm (s, 1H), δ = 12.4 ppm (broad s, 1H), the spectrum also contained a signal due to acetone, ca 0.05 mol. eq.; MS (M+H)⁺ 470/472.

Example 7 1-(6-Chloroindol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine

10

By an exactly analogous method, starting from 4-(4-pyridyl)benzoic acid and 1-(6-chloroindol-2-ylsulphonyl) piperazine, was prepared 1-(6-chloroindol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine as colourless crystals (145 mg) from acetone, m.p. 231-234 °C, ¹H NMR (d₆DMSO) δ = 3.0-3.2 ppm (broad s, 4H), δ = 3.4-3.8 ppm (broad s, 4H), δ = 7.1 ppm (s, 1H), δ = 7.2 ppm (dd, 1H), 7.5 ppm (m, 3H), δ = 7.7 ppm (m, 3H), δ = 7.8 ppm (d, 2H), δ = 8.6 ppm (d, 2H), δ = 12.4 ppm (broad s, 1H), the spectrum also contained a signal due to acetone, ca 0.25 mol. eq.; MS (M+H)⁺ 481/483.

The requisite 1-(6-chloroindol-2-ylsulphonyl) piperazine starting material was prepared as 20 follows:

1-(1-benzene sulphonyl-6-chloroindol-2-ylsulphonyl) piperazine (500mg, 1.18 mmol) was treated with sodium hydroxide solution (4 ml of 10M), and the suspension refluxed for 2 hrs. The reaction mixture was cooled to ambient temperature and carefully treated with 25 concentrated hydrochloric acid to pH 8; the resultant precipitate was filtered off, washed with water and dried to give 1-(6-chloroindol-2-ylsulphonyl) piperazine as a pale yellow solid which was used without further purification; ¹H NMR (d₆DMSO) δ = 3.1 ppm (m, 4H), δ = 3.2 ppm (m, 4H), δ = 7.1 ppm (s, 1H), δ = 7.2 ppm (dd, 1H), δ = 7.5 ppm (s, 1H), δ = 7.7 ppm (d, 1H); the spectrum also contained signals due to benzene sulphonic acid (ca 25 mol %); MS (M+H)⁺ 300/302.

The requisite 1-(1-benzene sulphonyl-6-chloroindol-2-ylsulphonyl) piperazine starting material was prepared as follows:

A solution of 1-benzene sulphonyl-6-chloroindol-2-ylsulphonyl chloride (5.0g, 12.8 mmol) in 5 dichloromethane (50ml) was added dropwise to a stirred solution of piperazine (6.62g, 6eq.) in dichloromethane (100ml), and the mixture stirred for a further 4 hrs. giving a yellow solution. This was then evaporated and dried overnight under high vacuum. The residue was purified by flash chromatography using Merck silica (Art. 9385), eluting with dichloromethane containing methanol (0-6%), to give 1-(1-benzene sulphonyl-6-chloroindol-2-ylsulphonyl) piperazine as 10 an off-white solid (3.68g, 68% yield); ^1H NMR (CDCl_3) δ = 2.75 ppm (m, 4H), δ = 3.3 ppm (m, 4H), δ = 7.45 ppm (d, 1H), δ = 7.6 ppm (m, 3H), δ = 7.7 ppm (m, 1H), δ = 7.75 ppm (d, 1H), δ = 8.0 ppm (d, 2H), δ = 8.15 ppm (s, 1H); MS ($\text{M}+\text{H})^+$ 440/442.

The requisite 1-benzene sulphonyl-6-chloroindol-2-ylsulphonyl chloride starting material may 15 be prepared by a method analogous to that reported in J. Med. Chem. 33 749 (1990), starting from 6-chloroindole.

Example 8 1-(5-Chlorobenzimidazol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine

20 A solution of 1-(5-chlorobenzimidazol-2-ylsulphonyl)-4-(t-butyloxycarbonyl) piperazine (860mg, 2.15 mmol) in dichloromethane/methanol (15ml of 1:1) was treated with an excess of hydrogen chloride gas as a saturated solution in ethyl acetate. After stirring for 4 hrs. the solvent was removed *in vacuo* and the residue dried under high vacuum. This was then suspended in DMF and treated sequentially with 4-(4-pyridyl)benzoic acid (428 mg, 2.15 25 mmol), triethylamine (0.6 ml, 4.3 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodi-imide hydrochloride (EDAC, 495 mg, 2.68 mmol). After stirring overnight the solvent was removed *in vacuo* and the residue taken up in dichloromethane (50ml). This was washed sequentially with water, saturated sodium bicarbonate solution, water and brine. Evaporation of the solvent gave a residue which was purified by chromatography (MPLC on Merck Art 9385 silica, 30 gradient eluting with ethyl acetate containing 0-8.0% methanol) to give 1-(5-chlorobenzimidazol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine as colourless crystals

(370 mg) from ethanol, m.p. 242-244 °C, ^1H NMR (d_6DMSO) δ = 3.0-3.4 ppm (broad s, 4H), δ = 3.4-3.8 ppm (broad s, 4H), δ = 7.4ppm (d, 1H), δ = 7.5ppm (d, 2H), δ = 7.6-7.8ppm (m, 4H), δ = 7.85ppm (d, 2H), δ = 8.6ppm (d, 2H), δ = 14.0ppm (broad s, 1H); MS ($\text{M}+\text{H}$) $^+$ 482/484.

5

The requisite 1-(5-chlorobenzimidazol-2-ylsulphonyl)-4-(t-butyloxycarbonyl) piperazine starting material was prepared as follows:

A suspension of 5-chloro-2-thiolbenzimidazole (500mg, 2.71 mmol) in acetic acid (2.5 ml) and 10 water (10 ml) was cooled to 5 °C and chlorine gas bubbled in slowly, keeping the temperature below 7 °C. The flow of chlorine was maintained until no more was absorbed, and then for a further 15 mins., after which time the reaction was purged with argon. The suspension was filtered off, washed quickly with water and then added in small portions to a stirred, cooled (5°C) solution of N-Boc piperazine (1.26g, 6.78 mmol) in dichloromethane (20 ml). After 15 stirring for 1 hr. At ambient temperature, the reaction mixture was diluted with more dichloromethane (30 ml) and washed sequentially with citric acid solution (30 ml, 1M), sat. brine (30 ml), water (2x30 ml) and sat. brine (30 ml). The solution was dried (Phase-Sep paper) and evaporated to give 1-(5-chlorobenzimidazol-2-ylsulphonyl) 4-(t-butyloxycarbonyl) piperazine as a brown foam (880 mg, 81% yield), which was used without further purification; 20 ^1H NMR (CDCl_3) δ = 1.4ppm (s, 9H); δ = 3.4 ppm (m, 4H), δ = 3.6 ppm (m, 4H), δ = 7.4ppm (d, 1H), δ = 7.4-7.6ppm (broad s, 1H), δ = 7.7-7.9ppm (broad s, 1H); MS ($\text{M}+\text{H}$) $^+$ 401/403 (w), ($\text{M}+\text{H} - 56$) $^+ 345/347$ (s).

